

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **December 18, 2012**

iBio, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-35023

(Commission File Number)

26-2797813

(IRS Employer Identification No.)

9 Innovation Way, Suite 100

Newark, Delaware 19711

(Address of principal executive offices, including zip Code)

(302) 355-0650

(Registrant's telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) Resignation of Director

On December 18, 2012, Jules A. Müsing resigned from the Board of Directors (the “Board”) of iBio, Inc. (the “Company”).

(d) Appointment of New Director

On December 18, 2012, the Board voted to appoint Seymour Flug to serve on the Board, filling the vacancy created by Mr. Müsing’s departure. Mr. Flug will be one of the Board’s Class III directors, whose members’ terms expire at the Company’s annual meeting to be held in late 2014.

There is no arrangement or understanding between Mr. Flug and any other person, pursuant to which Mr. Flug is to be appointed as a director. Mr. Flug is not a party to any transactions that would require disclosure under Item 404(a) of Regulation S-K.

Mr. Flug was appointed to serve on the Audit Committee of the Board.

In connection with his appointment, Mr. Flug was granted a stock option to purchase 60,000 shares of the Company’s common stock under the Company’s stock incentive plan, which shall vest in three equal annual installments beginning on the first day of Mr. Flug’s service, at an exercise price set at the last trading price on the date of appointment.

On December 21, 2012, the Company issued a press release announcing the appointment of Mr. Flug as well as the addition of Andrea Corcoran, the Company’s new Senior Vice President, Finance and Strategy. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

At the Company’s 2012 Annual Meeting of Stockholders, Proposals 1 and 2 were each approved by the Company’s stockholders. The proposals are described in detail in the definitive proxy statement filed by the Company with the Securities and Exchange Commission on November 16, 2012. The final voting results of the 2012 Annual Meeting are set forth below.

Proposal 1 - Election of Directors - The Company’s stockholders elected Robert B. Kay, General James T. Hill and Arthur Y. Elliott, Ph.D. to serve as Class I directors of the Company for a three-year term expiring in 2015. The voting results for each of these individuals were as follows:

Director	Votes For	Votes Withheld	Broker Non-Votes
Robert B. Kay	25,506,547	246,803	15,862,617
General James T. Hill	25,507,958	245,392	15,862,617
Arthur Y. Elliott, Ph.D.	25,520,471	232,879	15,862,617

Proposal 2 - Ratification of the Company’s Independent Registered Public Accounting Firm - The Company’s stockholders ratified the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2013. The voting results were 41,345,742 shares “FOR,” 195,670 shares “AGAINST,” and 74,555 abstentions.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release of iBio, Inc., issued December 21, 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

IBIO, INC.

Date: December 21, 2012

By: /s/ Douglas Beck, CPA

Douglas Beck, CPA
Chief Financial Officer

iBio Announces New Appointment to Board of Directors and New Addition to Executive Management Team

- Seymour Flug, former chairman of Diner's Club International, joins iBio Board of Directors

- Andrea Corcoran, an experienced biotech executive, is added to iBio executive management team

NEWARK, Del., Dec. 21, 2012 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) announced today the appointment of Seymour Flug to the iBio Board of Directors and the addition of Andrea Corcoran, as Senior Vice President, Finance and Strategy, a newly created position on the iBio leadership team. Mr. Flug most recently was the former chairman, president and CEO of Diner's Club International and a managing director at Citibank. Previously he served as a Senior Vice President at Hess Oil Company. Ms. Corcoran joins iBio following roles with increasing responsibility for corporate, financial and business development strategy formation and operations at Idenix Pharmaceuticals, Inc., and Tolerx, Inc., each biopharmaceutical companies engaged in the discovery and development new and innovative pharmaceutical products.

"Sy is a veteran executive with extensive experience in finance and deal making," said iBio's Executive Chairman and Chief Executive Officer, Robert B. Kay. "We expect that his wide-ranging background in the financial operations of multi-national companies and business combinations will be of great benefit to iBio as we continue to execute on our long-term strategic objectives."

On the addition of Ms. Corcoran to the executive management team, Robert Erwin, President of iBio commented, "With the Company's recent progress and current momentum, Andrea is arriving at a perfect time to apply her experience and proven capabilities to manage our growth and to optimize and implement our business development and finance strategies. As we address the opportunities ahead of us, we look forward to Andrea's contributions as an integral member of our iBio team."

iBio also announced today that Jules Musing has resigned from iBio's Board of Directors. "We are grateful for Jules' service on the Board," said Mr. Kay.

About iBio, Inc.

iBio develops and offers product applications of its iBioLaunch™ and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch™ platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems include: success with proteins difficult or impossible to produce with other methods; broadly applicable to biologics, including therapeutic proteins and vaccines; production time measured in weeks instead of

months or more. Additional benefits include a practically unlimited surge capacity for remedial action against bioterrorism and pandemic disease; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production. The iBioModulator™ platform is complementary to the iBioLaunch™ platform and enables significantly improved vaccine products with higher potency and greater duration of effect. The iBioModulator™ platform can be used with most recombinant expression technologies for vaccine development and production. Further information is available at: www.ibioinc.com

Forward-Looking Statements

Statements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the expected benefit to be derived by iBio from Mr. Flug's appointment on the Board of Directors and the anticipated contributions to be made by Ms. Corcoran. These statements are subject to numerous factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. Such risks and uncertainties may include lack or insufficiency of available capital, intellectual property protection issues, competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.

Contacts:

Corporate:

Robert Erwin, President
iBio, Inc.
302-355-2335
rerwin@ibioinc.com

Investors:

Douglas Beck, CFO
iBio, Inc.
302-355-9452
ir@ibioinc.com
